The Association Between Aging Microenvironment And Tumor Progression

Contact: joanna.jia@wecistanche.com / WhatsApp: 008618081934791

"Aging" is generally defined as the time-dependent functional decline affecting organisms, and the time-dependent accumulation of cellular damage in organisms is considered a general cause of aging. On the other hand, tumors and senescence appear to be opposite processes: tumors are the result of abnormally enhanced cellular fitness, while senescence is characterized by a loss of fitness. Abnormal growth benefits can eventually lead to tumorigenesis. From this perspective, "tumor" and "senescence" are two different manifestations of the accumulation process of cellular damage. Molecular signatures on nine cells of human aging: genomic instability, loss of proteostasis, telomere attrition, mitochondrial dysfunction, altered epigenetic traits, altered intercellular communication, dysregulated nutrient sensing, cellular senescence, and stem cell exhaustion.

Anti-aging and anti-tumor: sistanch

The aging microenvironment and tumor progression: The aging microenvironment drives tumor progression. Interactions between tumor cells and the senescent microenvironment, as demonstrated by the fact that senescence reprograms interstitial fibroblast populations, extracellular matrix (ECM), and immune infiltration to drive tumor initiation and progression. The aging microenvironment can also negatively influence the control of tumor cell response to antitumor drug treatment. Many factors involved in the evolution of senescent tissue lead to the eventual transformation of self-renewing tissue into malignant and proliferative growth, or to growth arrest (ie, cellular senescence), apoptosis, and degradation of other cellular and tissue structural components. The exponential increase in tumor risk and many of these degenerative features in tissues and cells with age is absolutely related to the complex interrelationship between the local and systemic microenvironments of aging and their contribution to tumor initiation and progression. During aging, different stromal tissue environments throughout the body may undergo differential reprogramming, affecting tumor growth and progression.

Matrix homeostasis in aging: The matrix microenvironment within tissues, composed of various components, including fibroblasts, endothelial cells, pericytes, adipocytes, ECM, and immune cells, plays an important role in tissue homeostasis. Fibroblasts are the most common stromal component of tissues throughout the body. Changes that occur in fibroblasts during aging can also vary by organ site and are often involved in aging. Antagonistic pleiotropy in the context of aging is defined as a single genetic trait that induces a beneficial and health-enhancing phenotype early in life, but in older organisms it becomes harmful. Cellular senescence is a classic example of antagonistic pleiotropy, and the accumulation of senescent cells is one of the key pathological features associated with aging. One of the key features of cellular senescence is widespread alterations in epigenetic gene expression, with cells markedly increasing the secretion of proinflammatory cytokines, chemokines, growth factors, and proteases; this secretome is defined as a secretory phenotype associated with senescence. SASP is thought to consist of approximately 75 secreted factors, many of which have been identified in studies using oncogene-induced senescence models, and may be beneficial, alerting the immune system to tissue damage or the need to clear senescent cells, but may also be harmful because of its role in driving tumor cell invasion and progression. Its cellular senescence plays an important role in the regulation of tumor cells, where the oncogenic transformation of normal cells can lead to their senescence, initially preventing their growth. Despite the homeostatic importance of programmed senescence in stromal cells, age-related accumulation of SASP cells over time can reprogram the primary and metastatic microenvironments into a state more conducive to malignant cell growth, thereby promoting cancer progression. The mode of initiation of cellular senescence induced by oncogenes, replication, stress, or therapy significantly alters the SASP factors secreted by these cells, and not all cellular senescence is created equal, nor can it truly be indicative of senescence.

Cistanche deserticola powder supplements effectively improve physiology and anti-tumor and anti-aging

Structure and aging ECM: In addition to secreted factors, fibroblasts also play a role in ECM formation. The ECM is primarily responsible for the structural integrity of most tissues and controls protein and cell-specific transport in vivo. Components of the ECM serve as ligands for cell surface receptors, such as integrins, and control central homeostasis processes, including adhesion, apoptosis, proliferation, migration, survival, and differentiation. The ECM is highly dynamic, undergoing constant remodeling under the control of a delicate balance between degradation and deposition. Loss of tissue ECM integrity contains one of the hallmarks of cancer, and its dysregulation is closely associated with tumor progression and metastasis. The ECM microenvironment varies widely between different organs due to the complex changes required for specific organ structures and functions. While there is a diversity of many biochemical cues in the ECM microenvironment, heterogeneity in stiffness and elasticity is also observed throughout the body, factors that change dramatically with age. Pathologically, the diversity of ligand expression and stiffness plays an important role in malignant tumor progression.

Tumor immune microenvironment and aging: The immune system plays a crucial role in recognizing and suppressing malignant tissue growth. Therefore, evasion of immune surveillance is a critical step in tumor initiation, growth, and metastasis. One of the hallmarks of aging is an increase in low-grade chronic inflammation throughout the body, a process known as "inflammation." This persistent inflammatory response leads to tissue degeneration and destruction of acute inflammation and is closely related to the induction and progression of malignant tumors. Immunosenescence is another factor that contributes to many age-related diseases. There are many factors involved in this process: atrophy of the thymus, changes in the quantity and quality of T cells, etc. Inflammation appears to play a key role in accelerating many of these processes, as the chronic inflammatory signals and responses associated with this process are often inhibitory. Age-induced immune senescence occurs primarily in effector T cells and other immune cell types critical for tumor immunity. These changes may lead to the activation and infiltration of more immunosuppressive cell populations in older adults, which may be key to their increased susceptibility to cancer and metastasis.

Benefit of cistanche tcm :anti-aging & anti-tumor

Aging and Antineoplastic Drug Therapy Treatment Response In the treatment of older cancer patients, age-related health concerns determine whether potentially beneficial treatments can be used safely at standard doses and improve survival. About 50% of tumors occur in patients over the age of 65, yet clinical trial data on patients over this age are very limited. Forty percent of patients enrolled in clinical trials of antineoplastic drug therapy were over 65 years old, and 10 percent were over 75 years old. The veracity of its representation of the true clinical age at the onset of most tumors is debatable. Targeted chemotherapy-induced acceleration of age-related tumor events may have potential clinical benefits, resulting in reduced cytotoxicity and improved survival. In many cases, chemotherapy in older patients is well tolerated and prolongs survival, regardless of tumor location. Considering that a large clinical factor in deciding chemotherapy regimens in the elderly is whether the benefits of treatment outweigh the side effects, further studies are needed to better understand the cytotoxic effects at the molecular level. Targeted therapy represents a standard of personalized care, designed to target tumor cells, or TME, to specifically drive individual growth and progression of that tumor type. While there are many patients whose tumors initially respond to targeted therapy, a large proportion becomes resistant. There are many studies showing that direct changes in intrinsic signaling pathways are associated with resistance to targeted therapy; however, the direct relationship between these changes and the microenvironment is not well defined, especially in relation to age. Targeted therapies tend to have fewer off-target effects than chemotherapy and radiotherapy, and as a result, cells appear to undergo more intrinsic changes, based on genetic mutations, epigenetic alterations, and genomic instability, to induce drug resistance TME. The immune spectrum and function change dramatically with age, and treatments targeting the immune system of the elderly have considerable clinical implications. Despite this, there are still few direct studies evaluating the efficacy of immunotherapy in aged cancer models. An in-depth review of published datasets revealed that currently available immune checkpoint inhibitors are highly effective in older adults.

costanche improves the anti-aging microenvironment

The aging microenvironment may have a dramatic impact on tumor progression. Age-related normal changes in stromal and immune populations may collectively drive tumor cells from a naive or slow-growing state to highly aggressive and metastatic disease.